Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488227 | 1.00 | HTR6 (0.54) | HTR6CHRNB2CHRNA5CHRNA7CHRNA4 | |
| Hydrochloric Acid SCHEMBL28216900 | 0.98 | HTR6 (0.55) | HTR6CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL2606119 | 0.95 | ADRA2A (0.53) | HTR6 | |
| SCHEMBL11470450 | 0.93 | ADRA2A (0.51) | HTR6 | |
| Ammonia Solution, Strong SCHEMBL3645001 | 0.93 | ADRA2A (0.51) | HTR6 | |
| SCHEMBL25645586 | 0.93 | ADRA2A (0.51) | HTR6 | |
| Ammonia Solution, Strong SCHEMBL29771408 | 0.87 | HTR1D (0.49) | HTR6 | |
| SCHEMBL13162975 | 0.84 | HTR1D (0.52) | HTR6CHRNB2CHRNA4 | |
| Styrene SCHEMBL28422467 | 0.83 | HTR6 (0.44) | HTR6CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL2691261 | 0.82 | SLC18A2 (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250209-B1 | COMT INHIBITING METHODS AND COMPOSITIONS | LIEBER INST FOR BRAIN DEVELOPMENT (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH | 2021-04-01 | — | — | US | disclosed |
| US-10479790-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE FOR BRAIN DEVELOPMENT (US) | 2019-11-19 | — | — | US | disclosed |
| WO-2019183245-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | LIEBER INSTITUTE, INC. | 2016-08-04 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212187-B2 | Nitrogen-containing compounds and pharmaceutical compositions thereof for the treatment of atrial fibrillation | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARMA CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | OTSUKA PHARCACEUTICAL CO LTD (JP) | 2014-11-20 | — | — | US | disclosed |
| WO-2008116958-A1 | METHOD FOR PREPARATION OF AN ALUMINOSILICATE WITH FERRIERITE STRUCTURE FROM GELS CONTAINING TETRAMETHYL AMMONIUM AND BENZYLMETHYLPYRROLIDINE, AND USES THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2008-10-02 | — | — | WO | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7402579-B2 | Quinobenzoxazine analogs and compositions | CYLENE PHARMACEUTICALS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1874731-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | Cylene Pharmaceuticals, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006113509-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| US-4279918-A | ANTIDEPRESSANTS, STIMULANTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK G.M.B.H. (DE) | 1981-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYP2W1, NQO2, UGT2B7 | HTR6 1977/4885CHRNB2 1408/4885CHRNA5 1002/4885 |
| US-20140343277-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | HTR6 1505/4885CHRNB2 157/4885CHRNA5 60/4885 |
| US-20140343278-A1 | NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION | KCNH2, KCNH1, KCNH3 | HTR6 1505/4885CHRNB2 157/4885CHRNA5 60/4885 |
| US-20160222011-A1 | COMT Inhibiting Methods and Compositions | COMT, SLC6A3, MAOA | HTR6 119/4885CHRNB2 223/4885CHRNA5 121/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | HTR6 1881/4885CHRNB2 849/4885CHRNA5 248/4885 |
| US-20210094950-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, CSNK1E, CSNK1G3 | HTR6 1086/4885CHRNB2 658/4885CHRNA5 852/4885 |
| US-10479790-B2 | COMT inhibiting methods and compositions | COMT, SLC6A3, MAOA | HTR6 119/4885CHRNB2 223/4885CHRNA5 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.